Virogenetics Corporation

Sanofi Pasteur Inc.

Consejo Superior De Investigaciones Cientificas

Arizona State University

Ippox Foundation

Ludwig Institute for Cancer Research Limited

Arizona Board of Regents, a Body Corporate

Aventis Pasteur Limited

Connaught Technology Corporation

Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Universitéde Montreal

Connaught Laboratories Limited

Centre Hospitalier Universitaire Vaudois

Academisch Zikenhuis Leiden

James Tartaglia

Enzo Paoletti

William I Cox

Jill Taylor

Russell Robert Gettig

Steven E Pincus

Michel Albert Riviere

Bertram L Jacobs

Giuseppe Pantaleo

Keith J Limbach

Charles De Taisne

Karen Kibler

Marion E Perkus

Alexandre Harari

Gerard P Johnson

Elizabeth K Norton

Jean-Christophe Francis Audonnet

Thierry Calandra

Thierry Roger

Mariano Esteban

Cornelius Melief

Rafick-Pierre Sekaly

Neil L Berinstein

Philippe Moingeon

Michel Henri Klein

Thierry R Boon-Falleur

Genoveffa Franchini

John A Tine

Louis Ross

Elias El Haddad

Hector Martinez

Pierre Vander Bruggen

Robert C Gallo

George N Pavlakis

Benjamin Rovinski

Mary E Ewasyshyn

Dennis L Panicali

Linda R Gritz

Shi-Xian Cao

Fei-Long Yao

Roy Persson

Mark Parrington

George A Cates

Scott J Goebel

Zdenek Hel

Diane M Gajewczyk

Elias Haddad

Neil Berinstein

Phillipe Moingeon

Brian Barber

Bertram Jacobs

Alexandri Harari

Mario Esteban

Guiseppe Pantaleo

The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Modified immunization vectors

The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.

Multi-antigen vectors of melanoma

The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.

Immunogenic polypeptides encoded by MAGE minigenes and uses thereof

An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.

Method of inducing and/or enhancing an immune response to tumor antigens

This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.

Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors

Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV vaccine followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID) given eight months after the initial challenge without any intervening booster.

ALVAC/FIV constructs

Recombinant viruses containing DNA coding for a rabies virus antigen, such as rabies virus G are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom are useful for eliciting an immunological against rabies virus, and, the gene products and antibodies elicited thereby are useful in assays.

Poxvirus-rabies recombinants and compositions and methods employing the recombinants

Attenutated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wiltype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GMCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

Pox virus comprising DNA sequences encoding CEA and B7 antigen

Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(&plus;pro)(IIIB), gp120(MN)(&plus;transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(&plus;pro)(IIIB), gp120(MN) (&plus;transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. DNA from the recombinant viruses are useful as probes or, for generating PCR primers or for immunization. Also disclosed and claimed are HIV immunogens and modified gp160 and gp120.

Immunodeficiency recombinant poxvirus

Attenuated recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least on of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IFN&ggr;; IL-4; GNCSF; IL-12; B7; erb-B-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

Vaccina virus comprising cytokine and/or tumor associated antigen genes

Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid protein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.

Poxvirus&mdash;canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants

Growing community of inventors

Aurora, Canada

James Tartaglia